Filtreler
The effect of preoperative dexamethasone administration on nause-vomiting and pain in thyroidectomy [?iroidektomi operasyonlarinda preoperatif uygulanan deksametazonun postoperatif bulanti-kusma ve agriya etkisi]

Altunkaya H. | Özer Y. | Cihan A. | Özkoçak I. | Demirel C.B.

Article | 2003 | Anestezi Dergisi11 ( 2 ) , pp.131 - 135

In this study; it is aimed to evaluate the effect of preoperative single dose dexamethasone on postoperative nausea, vomiting (PONV) and pain patients planned for thyroidectomy. Forty patients, ASA I-II, scheduled for thyroidectomy were included in this randomized, double-blinded and placebo controlled study. The patients were randomly divided into two groups. A blind investigator administered dexamethasone 8 mg iv (Group D, n=20) or 2 ml saline (Group S, n=20) to the patients. Anaesthesia induction was performed with propofol 2mg kg-1, 2 µg kg-1 fentanyl and rocuronium 0.6 mg kg-1. Sevoflurane IMAC was used in all patients for the . . .maintenance of anaesthesia. Pain (VAS pain scale), PONV (0-3 scale), the time for first analgesic need, total analgesic need, reaction to dressing, infection of insicion and mobilization time were recorded at postoperative 0, 15, 30, and 45th min and two hours intervals in first day. The postoperative VAS scores, PONV value and total analgesic need of Group D were significantly lower than Group S (p<0.05). There was no difference between the reaction to dressing and mobilization time of the groups. In conclusion preoperative dexamethasone administration less postoperative pain and PONV in thyroidectomy Daha fazlası Daha az

The Effect of Dexamethasone Intravitreal Implant on Retinal Nerve Fiber Layer in Patients Diagnosed with Branch Retinal Vein Occlusion

Ayar O. | Alpay A. | Koban Y. | Akdemir M.O. | Yazgan S. | Canturk Ugurbas S. | Ugurbas S.H.

Article | 2017 | Current Eye Research42 ( 9 ) , pp.1287 - 1292

Purpose: To evaluate the effect of a single dose of intravitreal dexamethasone (DEX) implant on retinal nerve fiber layer (RNFL) thickness in patients with branch retinal vein occlusion (BRVO) in a 6-month period. Materials and methods: This retrospective observational study included the patients with BRVO who received intravitreal DEX implant and whose assessment included the baseline RNFL thickness measurements. The data of 26 eyes of 24 patients were retrospectively analyzed. Spectral domain optic coherence tomography was used to measure peripapillary RNFL thickness in six regional subfields. Intraocular pressure (IOP) values at . . .each visit were recorded. The data of single dose DEX implant during 6 months were assessed. Results: The mean preoperative and postoperative 6th month nasal RNFL values were 85.4 ± 23.0 µm and 82.1 ± 17.6 µm, respectively, and the difference between the measurements was not statistically significant (p = 0.372). There was a slight decrease in the mean RNFL values postoperatively compared to the baseline values in all quadrants except supero-temporal quadrant; however, none of them reached statistically significant level (p > 0.05). The mean IOP values before and 6 months after implantation were 15.7 ± 2.9 mmHg and 16.5 ± 4.2 mmHg, respectively. The difference between the 6th month IOP values and baseline IOP values was not statistically significant (p = 0.236). Conclusion: Intravitreal DEX implant seems to have no adverse effect on RNFL thickness in BRVO patients in a 6-month period. © 2017 Taylor & Francis Group, LLC Daha fazlası Daha az

Dual synergistic effect: The effect of dexamethasone plus carnitine on skin flap survival

Kargi E. | Deren O. | Babuccu O. | Hosnuter M. | Erdogan B.

Article | 2004 | Annals of Plastic Surgery53 ( 5 ) , pp.488 - 491

Dexamethasone has well-known useful effects in dealing with the progression of necrosis. Carnitine is an endogenous cofactor, for having a regulatory action on the energy flow from different oxidative sources. The aim of this study was to determine whether combined local dexamethasone and systemic carnitine administration would result in an additive enhancement of skin flap survival in the rat model. A rectangular (3 cm X 11 cm) dorsal random skin flap was elevated on the rats and then sutured back into its original site with separate sutures. Overall, 40 rats were allocated randomly into 4 groups: Group 1 (control group, n = 10), g . . .roup 2 (Dexamethasone group, n = 10, 2.5 mg/kg), group 3 (carnitine group, n = 10, 100 mg/kg), group 4 (dexamethasone plus carnitine group, n = 10). The mean flap survival area was 57.50 ± 5.2% (mean survival area ± SD) in control group (group 1), 71.5 ± 4.8% in the dexamethasone group (group 2), 73.0 ± 5.5% in the carnitine group (group 3), 85.30 ± 6.1% in the dexamethasone plus carnitine group (group 4). In conclusion, based on the findings of this experimental study, the synergistic effect of carnitine and dexamethasone on skin flap viability is determined Daha fazlası Daha az

Comparison of reducing effect on lung injury of dexamethasone and bosentan in acute lung injury: an experimental study

Araz, Omer | Demirci, Elif | Ucar, Elif Yilmazel | Calik, Muhammet | Pulur, Didem | Karaman, Adem | Yayla, Muhammed

Article | 2013 | MULTIDISCIPLINARY RESPIRATORY MEDICINE8 , pp.488 - 491

Background: Different medical therapies are employed in acute lung injury (ALI) but there is still a debate about the efficacy of these drugs. Among these therapies steroids are clinically applied and bosentan is experimentally studied. The aim of this study was to evaluate the efficacy of these two drugs to treat inflammation in ALI by histopathological comparison. Methods: The five experimental groups (n = 5 per group) were: saline control (Group I); lipopolysaccharide (LPS) + saline (Group II); LPS + dexamethasone (Group III); LPS + 50 mg/kg bosentan (Group IV); and LPS + 100 mg/kg bosentan (Group V). Bosentan was administered or . . .ally one hour before and 12 hours after LPS treatment. Dexamethasone was administered intraperitoneally in three doses of 1 mg/kg; one dose was co-administered with LPS and the other two doses were given respectively 30 minutes before and after LPS treatment. Vasodilation-congestion, hemorrhage, polymorphonuclear leukocyte (PMN) infiltration, mononuclear leukocyte (MNL) infiltration, alveolar wall thickening, alveolar destruction/emphysematous appearance, and focal organization were the parameters used as criteria for evaluating inflammation and efficacy of treatment. Results: Compared to the LPS-only group (Group II), dexamethasone treatment (Group III) resulted in significant improvements in vasodilation-congestion, hemorrhage, PMN and MNL infiltration, alveolar wall thickening and emphysematous areas. Treatment with 50 mg/kg dose of bosentan (Group IV) also resulted in significant improvements in hemorrhage, PMN and MNL infiltration, alveolar wall thickening and alveolar destruction. Reducing lung injury and reparative effects of 100 mg/kg bosentan were significant in all parameters. Conclusions: Bosentan is as effective as dexamethasone for treating lung injury in ALI. Bosentan at 100 mg/kg can be recommended as a first treatment choice based on its significant reducing lung injury and reparative effects Daha fazlası Daha az

6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms